Breaking News
Get 50% Off 0
📈 Q4 Earnings Alert! Critical earnings dates you can't miss
See Calendar
Close

Oncodesign (ALONC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Oncodesign historical data, for real-time data please try another search
14.42 0.00    0.00%
08/12 - Real-time Data. Currency in EUR
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 14.42 - 14.44
Type:  Equity
Market:  France
ISIN:  FR0011766229 
Oncodesign 14.42 0.00 0.00%

Oncodesign Company Profile

 
Get an in-depth profile of Oncodesign, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

236

Equity Type

ORD

Oncodesign Société Anonyme operates as a biopharmaceutical company focused on precision medicine for the discovery and development of therapies and diagnostic solutions for advanced and resistant cancers. The company provides drug discovery services and develops therapeutic and diagnostic solutions using proprietary technologies such as Nanocyclix for macrocyclization of small molecules and the OncoSniper program, which applies artificial intelligence to oncology drug discovery. It offers integrated drug discovery services, including target identification, medicinal chemistry, pharmacology, metabolism, pharmacokinetics, bioanalysis, and biobank management. The company conducts research collaborations for new drug candidates in oncology, rare diseases, and fibrosis, and has developed experimental cancer models and radiotracers such as Florepizol for non-small cell lung cancer. It also participates in biomarker programs and manages clinical studies for diagnostic and therapeutic compounds. The company serves biotechnology and pharmaceutical companies, as well as hospitals. The company was founded in 1995 and is based in Dijon, France.

Contact Information

Address 20 rue Jean Mazen BP 27627
Cedex Dijon, 21076
France
Phone 33 3 80 78 82 60
Fax 33 3 80 78 82 61
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALONC Comments

Write your thoughts about Oncodesign
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email